Derenzini et al.’s research successfully integrated gene expression profiling with clinical prognostication in diffuse large B-cell lymphoma (DLBCL), particularly highlighting the role of MYC and BCL2 in this type of cancer [26]. This evidence concerns the gene BCL2 and cancer.